Patent · US Active

Triazine derivatives as kinase inhibitors

US8785628B2 · kind B2 · utility

0Cited by
0References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 2, 2010
Grant dateJul 22, 2014
Priority date
Expiry dateDec 28, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D401/14
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.